# The Safety and Tolerability of SerpinPC in Healthy Men and in Men with Severe Blood Disorders (haemophilia a and B)

> **NCT04073498** · PHASE1,PHASE2 · COMPLETED · sponsor: **ApcinteX Ltd** · enrollment: 39 (actual)

## Conditions studied

- Hemophilia a
- Hemophilia B

## Interventions

- **DRUG:** SerpinPC
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04073498
- **Lead sponsor:** ApcinteX Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-14
- **Primary completion:** 2024-09-26
- **Final completion:** 2024-09-26
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2025-02-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04073498

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04073498, "The Safety and Tolerability of SerpinPC in Healthy Men and in Men with Severe Blood Disorders (haemophilia a and B)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04073498. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*